Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2001 2
2002 2
2003 9
2004 18
2005 26
2006 23
2007 24
2008 26
2009 25
2010 20
2011 6
2012 6
2013 7
2014 30
2015 37
2016 37
2017 54
2018 46
2019 56
2020 74
2021 82
2022 72
2023 94
2024 78
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

771 results

Results by year

Filters applied: . Clear all
Page 1
Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.
Fazili T, Bansal E, Garner D, Gomez M, Stornelli N. Fazili T, et al. Int J Antimicrob Agents. 2023 Apr;61(4):106749. doi: 10.1016/j.ijantimicag.2023.106749. Epub 2023 Feb 8. Int J Antimicrob Agents. 2023. PMID: 36758775 Review.
Dalbavancin is a parenteral lipoglycopeptide antibiotic derived from teicoplanin, an analogue of vancomycin. ...Almost all patients received dalbavancin as sequential therapy following standard-of-care antibiotics. The overall clinical efficacy of dalbavancin …
Dalbavancin is a parenteral lipoglycopeptide antibiotic derived from teicoplanin, an analogue of vancomycin. ...Almost all patients r …
Dalbavancin.
Barberán J, de la Cuerda A, Barberán LC. Barberán J, et al. Rev Esp Quimioter. 2021 Sep;34 Suppl 1(Suppl1):26-28. doi: 10.37201/req/s01.07.2021. Epub 2021 Sep 30. Rev Esp Quimioter. 2021. PMID: 34598419 Free PMC article. Review.
Dalbavancin is a long-acting antimicrobial agent with an excellent in vitro activity against Gram-positive pathogens, including staphylococcal biofilms. ...
Dalbavancin is a long-acting antimicrobial agent with an excellent in vitro activity against Gram-positive pathogens, including staph …
Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.
Molina KC, Miller MA, Mueller SW, Van Matre ET, Krsak M, Kiser TH. Molina KC, et al. Clin Pharmacokinet. 2022 Mar;61(3):363-374. doi: 10.1007/s40262-021-01088-w. Epub 2021 Dec 21. Clin Pharmacokinet. 2022. PMID: 34931283 Review.
Dalbavancin is a synthetic lipoglycopeptide that exerts its antimicrobial activity through two distinct modes of action, inhibition of cell wall synthesis and an anchoring mechanism. Compared with previous glycopeptide antibiotics, dalbavancin demonstrates improved …
Dalbavancin is a synthetic lipoglycopeptide that exerts its antimicrobial activity through two distinct modes of action, inhibition o …
Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
Gatti M, Andreoni M, Pea F, Viale P. Gatti M, et al. Drug Des Devel Ther. 2021 Aug 3;15:3349-3378. doi: 10.2147/DDDT.S313756. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34376971 Free PMC article. Review.
This article provides a critical reappraisal of real-world use of dalbavancin for off-label indications. A search strategy using specific keywords (dalbavancin, osteomyelitis, endocarditis, long-term suppressive therapy, bloodstream infection, pharmacokinetic/pharma …
This article provides a critical reappraisal of real-world use of dalbavancin for off-label indications. A search strategy using spec …
Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.
Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, Suen A, Mas Casullo V, Melnick D, Miceli R, Kovacevic M, De Bock G, Dunne MW. Rappo U, et al. Open Forum Infect Dis. 2018 Dec 10;6(1):ofy331. doi: 10.1093/ofid/ofy331. eCollection 2019 Jan. Open Forum Infect Dis. 2018. PMID: 30648126 Free PMC article.
Clinical cure at day 42 was seen in 65/67 (97%) and 7/8 (88%) patients in the dalbavancin group and SOC group in the CE population, respectively. Clinical response was similar in the dalbavancin group at day 21 (94%), 6 months, and 1 year (96%). Treatment-emergent a …
Clinical cure at day 42 was seen in 65/67 (97%) and 7/8 (88%) patients in the dalbavancin group and SOC group in the CE population, r …
Dalbavancin plasma concentrations in 133 patients: a PK/PD observational study.
Hervochon C, Hennart B, Leroy AG, Corvec S, Boutoille D, Senneville É, Sotto A, Illes G, Chavanet P, Dubée V, Bleibtreu A, De Carné MC, Talarmin JP, Revest M, Castan B, Bellouard R, Dailly É, Allorge D, Dinh A, Le Turnier P, Gregoire M; Dalbavancin Pharmacokinetics (DALBAP) study group. Hervochon C, et al. J Antimicrob Chemother. 2023 Dec 1;78(12):2919-2925. doi: 10.1093/jac/dkad331. J Antimicrob Chemother. 2023. PMID: 37864551
We aimed to describe dalbavancin concentrations in an observational retrospective multicentre study. METHODS: Patients from 13 French hospitals, treated with 1500 mg doses of dalbavancin and for whom therapeutic drug monitoring was performed from June 2018 to March …
We aimed to describe dalbavancin concentrations in an observational retrospective multicentre study. METHODS: Patients from 13 French …
Dalbavancin.
Anderson VR, Keating GM. Anderson VR, et al. Drugs. 2008;68(5):639-48; discussion 649-51. doi: 10.2165/00003495-200868050-00006. Drugs. 2008. PMID: 18370443 Review.
In a randomized, controlled, double-blind, multinational, phase III trial, dalbavancin was noninferior to linezolid, with clinical success rates of 88.9% and 91.2%. In a randomized, open-label, multicentre, phase II trial, clinical success rates were 94% with dalbavanci …
In a randomized, controlled, double-blind, multinational, phase III trial, dalbavancin was noninferior to linezolid, with clinical su …
Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review.
Ramadan MS, Gallo R, Lugarà M, Gambardella M, Oliva G, Bertolino L, Andini R, Coppola N, Zampino R, Durante-Mangoni E. Ramadan MS, et al. J Chemother. 2022 Oct;34(6):360-366. doi: 10.1080/1120009X.2021.2015649. Epub 2021 Dec 19. J Chemother. 2022. PMID: 34923922 Review.
Dalbavancin is a novel lipoglycopeptide antibiotic, characterized by a broad spectrum of activity against Gram-positive cocci. ...All adult patients diagnosed with spondylodiscitis and treated with dalbavancin were included across four Italian medical centers from J …
Dalbavancin is a novel lipoglycopeptide antibiotic, characterized by a broad spectrum of activity against Gram-positive cocci. ...All …
Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA, Zaharoff S, King H, Evans S, Hamasaki T, Lodise T, Ghazaryan V, Beresnev T, Riccobene T, Patel R, Doernberg SB, Rappo U, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group (ARLG). Turner NA, et al. Trials. 2022 May 16;23(1):407. doi: 10.1186/s13063-022-06370-1. Trials. 2022. PMID: 35578360 Free PMC article.
The primary objective is to compare the Desirability of Outcome Ranking (DOOR) at day 70 for patients randomized to dalbavancin versus standard of care. Key secondary endpoints include quality of life outcomes and pharmacokinetic analyses of dalbavancin. DISCUSSION: …
The primary objective is to compare the Desirability of Outcome Ranking (DOOR) at day 70 for patients randomized to dalbavancin versu …
Dalbavancin: a review.
Scheinfeld N. Scheinfeld N. Drugs Today (Barc). 2007 May;43(5):305-16. doi: 10.1358/dot.2007.43.5.1088618. Drugs Today (Barc). 2007. PMID: 17724497 Review.
The best-studied dosing schedule for dalbavancin involves the i.v. administration of 1 g of dalbavancin followed by 500 mg one week later. ...The side-effect profile of dalbavancin is mild, with headache and pyrexia being the most common adverse effects. D …
The best-studied dosing schedule for dalbavancin involves the i.v. administration of 1 g of dalbavancin followed by 500 mg one …
771 results